Isradipine in monotherapy and in combination with bopindolol: results of a 3-month multicentre study in hypertensives.
The antihypertensive effect and safety of treatment of hypertension with isradipine, a Ca antagonist of dihydropyridine group in monotherapy and in combination with the betablocker bopindolol was assessed in a multicentre study joined by six Czechoslovak centres. When administered alone to 102 patients with essential hypertension stages I and II, isradipine was effective in 59%. Forty-one per cent of patients required combined therapy. The treatment led to a marked decrease in diastolic BP in smokers and non-smokers alike. A significant rise in ALP was observed during therapy in both therapeutic regimens. A significant decrease in cholesterolaemia was found in patients treated with the isradipine-bopindolol combination. No serious adverse effects were seen during three-month follow-up.
Dzúrik
R
R
Clinic of Pharmacotherapy, Medical Bionics Research Institute, Bratislava, Czechoslovakia.
Fetkovská
N
N
Dvorák
I
I
Jonás
P
P
Markuljak
I
I
Petr
P
P
Kotlík
I
I
Widimský
J
J
D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D017275:Isradipine; D008297:Male; D008875:Middle Aged; D010869:Pindolol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use*; D012907:Smoking
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D011725:Pyridines; D002784:Cholesterol; D010869:Pindolol; C036007:bopindolol; D017275:Isradipine